SG11202011228TA - Magl inhibitors - Google Patents

Magl inhibitors

Info

Publication number
SG11202011228TA
SG11202011228TA SG11202011228TA SG11202011228TA SG11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA
Authority
SG
Singapore
Prior art keywords
magl inhibitors
magl
inhibitors
Prior art date
Application number
SG11202011228TA
Other languages
English (en)
Inventor
Cheryl A Grice
Daniel J Buzard
Michael B Shaghafi
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68534223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202011228T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of SG11202011228TA publication Critical patent/SG11202011228TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
SG11202011228TA 2018-05-15 2019-05-14 Magl inhibitors SG11202011228TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671985P 2018-05-15 2018-05-15
PCT/US2019/032289 WO2019222266A1 (fr) 2018-05-15 2019-05-14 Inhibiteurs de magl

Publications (1)

Publication Number Publication Date
SG11202011228TA true SG11202011228TA (en) 2020-12-30

Family

ID=68534223

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011228TA SG11202011228TA (en) 2018-05-15 2019-05-14 Magl inhibitors

Country Status (25)

Country Link
US (3) US10570106B2 (fr)
EP (1) EP3793547A4 (fr)
JP (1) JP2021523200A (fr)
KR (1) KR20210010475A (fr)
CN (1) CN112088001A (fr)
AR (1) AR115092A1 (fr)
AU (1) AU2019271123A1 (fr)
BR (1) BR112020000863A2 (fr)
CA (1) CA3097063A1 (fr)
CL (1) CL2020002927A1 (fr)
CO (1) CO2020013550A2 (fr)
CR (1) CR20200545A (fr)
DO (1) DOP2020000207A (fr)
EA (1) EA202092586A1 (fr)
GE (1) GEP20227443B (fr)
JO (1) JOP20200276A1 (fr)
MA (1) MA52635A (fr)
MX (1) MX2020012158A (fr)
NI (1) NI202000080A (fr)
PE (1) PE20211385A1 (fr)
PH (1) PH12020551934A1 (fr)
SG (1) SG11202011228TA (fr)
TW (1) TW201946906A (fr)
WO (1) WO2019222266A1 (fr)
ZA (1) ZA202006327B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP3515897B1 (fr) 2016-09-19 2021-08-18 H. Lundbeck A/S Carbamates de pipérazine comme modulateurs de magl et/ou de abhd6 et leur utilisation
PL3793565T3 (pl) 2018-05-14 2022-05-02 Gilead Sciences, Inc. Inhibitory MCL-1
AR115092A1 (es) 2018-05-15 2020-11-25 Abide Therapeutics Inc Inhibidores de magl
PE20210368A1 (es) 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
KR20210120020A (ko) * 2019-01-25 2021-10-06 하. 룬드벡 아크티에셀스카브 Magl 저해제에 의해 질병을 치료하는 방법
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US20210147367A1 (en) * 2019-11-15 2021-05-20 Lundbeck La Jolla Research Center, Inc. Crystalline forms of a magl inhibitor
JP7441947B2 (ja) 2019-11-26 2024-03-01 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体
US11702393B2 (en) 2020-04-21 2023-07-18 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
EP4198023A1 (fr) 2021-12-16 2023-06-21 Basf Se Composés de thiosemicarbazone actifs sur le plan pesticide
WO2023156402A1 (fr) 2022-02-17 2023-08-24 Basf Se Composés thiosemicarbazone à action pesticide

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (fr) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
DE69211015T2 (de) 1991-11-27 1997-01-09 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
AU1384795A (en) 1993-12-22 1995-07-10 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
WO1997018196A1 (fr) 1995-11-15 1997-05-22 Zeneca Limited Composes herbicides a base de pyrazole substitue
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
CA2386540A1 (fr) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Noueaux carbamates et urees
EP1201298A1 (fr) 2000-10-24 2002-05-02 Urea Casale S.A. Dispositif pour la condensation de carbamate
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (fr) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Procede de preparation de carbamates
CN1934097A (zh) 2004-02-18 2007-03-21 阿斯利康(瑞典)有限公司 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用
CA2589877A1 (fr) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
UA89514C2 (uk) 2004-12-30 2010-02-10 Janssen Pharmaceutica Nv Похідні феніламідів 4-(бензил)-піперазин-1-карбонових кислот та споріднені сполуки як модулятори гідролази амідів жирних кислот для лікування тривоги, болю та інших станів
WO2007052023A2 (fr) 2005-11-05 2007-05-10 Astrazeneca Ab Composes
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
EP2114941B1 (fr) 2006-12-22 2015-03-25 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2328897A1 (fr) 2008-07-16 2011-06-08 Schering Corporation Dérivés hétérocycliques bicycliques et leur utilisation comme modulateurs de gpcr
CA2743861A1 (fr) 2008-11-14 2010-05-20 The Scripps Research Institute Procede et composition se rapportant au ciblage de la mono-acylglycerol lipase
JP2012521425A (ja) 2009-03-23 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
TW201105655A (en) 2009-04-22 2011-02-16 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
JP2013510203A (ja) 2009-11-03 2013-03-21 バイエル・マテリアルサイエンス・アクチェンゲゼルシャフト 感光性ポリマー組成物における添加剤としてのフルオロウレタン
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
CN115521264A (zh) 2012-01-06 2022-12-27 法国施维雅药厂 治疗活性化合物及其使用方法
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
JP6100883B2 (ja) 2012-03-19 2017-03-22 アビデ セラピューティクス，インク． カルバマート化合物、及びその製造並びに使用
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
CA2917050A1 (fr) 2013-07-03 2015-01-08 Todd K. Jones Composes de pyrrolo-pyrrole carbamate et composes organiques associes, compositions pharmaceutiques et leurs utilisations medicales
WO2016014975A2 (fr) 2014-07-25 2016-01-28 Northeastern University Inhibiteurs, à base d'urée/carbamates, de faah, de magl ou des deux à la fois (faah/magl) et leurs utilisations
WO2016149401A2 (fr) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
EP3515897B1 (fr) 2016-09-19 2021-08-18 H. Lundbeck A/S Carbamates de pipérazine comme modulateurs de magl et/ou de abhd6 et leur utilisation
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
LT3541807T (lt) 2016-11-16 2021-12-27 H. Lundbeck A/S Magl inhibitoriaus kristalinė forma
BR112020003946A2 (pt) * 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
AR115092A1 (es) 2018-05-15 2020-11-25 Abide Therapeutics Inc Inhibidores de magl
KR20210120020A (ko) 2019-01-25 2021-10-06 하. 룬드벡 아크티에셀스카브 Magl 저해제에 의해 질병을 치료하는 방법

Also Published As

Publication number Publication date
EA202092586A1 (ru) 2021-03-10
EP3793547A4 (fr) 2021-11-17
AR115092A1 (es) 2020-11-25
PE20211385A1 (es) 2021-07-27
CL2020002927A1 (es) 2021-03-05
JOP20200276A1 (ar) 2020-11-02
CN112088001A (zh) 2020-12-15
TW201946906A (zh) 2019-12-16
WO2019222266A1 (fr) 2019-11-21
MX2020012158A (es) 2021-01-29
MA52635A (fr) 2021-03-24
DOP2020000207A (es) 2021-02-15
BR112020000863A2 (pt) 2020-12-08
EP3793547A1 (fr) 2021-03-24
CO2020013550A2 (es) 2020-11-10
GEP20227443B (en) 2022-11-25
PH12020551934A1 (en) 2021-06-21
KR20210010475A (ko) 2021-01-27
US11214557B2 (en) 2022-01-04
US20210206735A1 (en) 2021-07-08
US20190352273A1 (en) 2019-11-21
JP2021523200A (ja) 2021-09-02
AU2019271123A1 (en) 2020-11-26
US10570106B2 (en) 2020-02-25
US20200148653A1 (en) 2020-05-14
CA3097063A1 (fr) 2019-11-21
ZA202006327B (en) 2022-06-29
US11332453B2 (en) 2022-05-17
CR20200545A (es) 2020-12-17
NI202000080A (es) 2021-02-15

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
ZA202006327B (en) Magl inhibitors
IL276594A (en) FAP inhibitors
ME03759B (fr) Inhibiteurs de bromodomaine
IL269196A (en) New inhibitors
ZA201903100B (en) Magl inhibitors
IL266550A (en) Magl inhibitors
ZA201903099B (en) Magl inhibitors
ZA201908070B (en) Pyrazole magl inhibitors
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) pi4kiiibeta inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201809939D0 (en) Eastase inhibitor
ZA201807614B (en) Bromodomain inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors